

## **WHO Prequalification Programme**

### **WHO PUBLIC ASSESSMENT REPORT (WHOPAR)**

**PASS nātrijs sāls Olpha 5,52 g pulveris iekšķīgi lietojama šķīduma pagatavošanai<sup>1</sup>**

#### **p-Aminosalicylate sodium 5.52 g powder for oral solution**

para-aminosalicylate sodium 5.52 g powder for oral solution

Para-aminosalicylate sodium 5.52 g powder for oral solution was submitted in 2010 by JSC “Olainfarm” to be considered for prequalification and subsequently accepted for the WHO list of prequalified products for treatment of tuberculosis on 22 March 2011.

The holder of the marketing authorization changed to Olpha AS in October 2024.

Information on the site(s) involved in the manufacture of the product and the API is available at the products listing information <https://extranet.who.int/prequal/medicines/tb229>

The “Procedure for prequalification of pharmaceutical products<sup>2</sup>” defines specific evaluation mechanisms for products approved by regulatory authorities, which apply similar stringent standards for quality, safety and efficacy as those required by WHO.

The prequalification of this product by the WHO Prequalification Team: Medicines (PQTm), is based on the approval by the Latvian Authority “Zāļu Valsts aģentūra” (<http://www.zva.gov.lv>), in line with the “Guidelines on submission of documentation for prequalification of finished pharmaceutical products approved by stringent regulatory authorities”<sup>3</sup>.

Hence, no assessment of the data underlying this approval has been undertaken within the WHO Prequalification Programme.

However, according to the SRA guideline WHO may request additional data when considered necessary for the safe use of the product in regions relevant for prequalified products and such information may be included in the WHOPAR as a separate piece of information. In order to safeguard product quality throughout its entire intended shelf-life in hot and very humid areas, stability studies under the conditions defined for Climatic Zones IVb have been requested from the Applicant<sup>4</sup>.

---

<sup>1</sup> Trade names are not prequalified by WHO. This is the National Medicines Regulatory Authority’s responsibility. Throughout this WHOPAR the proprietary name is given as an example only.

<sup>2</sup> [https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/prequalification/trs961-annex10-who-procedure-prequalification.pdf?sfvrsn=85029f47\\_2](https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/prequalification/trs961-annex10-who-procedure-prequalification.pdf?sfvrsn=85029f47_2)

<sup>3</sup> [https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/prequalification/trs986-annex5.pdf?sfvrsn=8aae767d\\_2](https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/prequalification/trs986-annex5.pdf?sfvrsn=8aae767d_2)

<sup>4</sup> [https://extranet.who.int/prequal/sites/default/files/document\\_files/48%20Stability%20data%20SRA%20FPPs\\_March2016\\_newtempl.pdf](https://extranet.who.int/prequal/sites/default/files/document_files/48%20Stability%20data%20SRA%20FPPs_March2016_newtempl.pdf)

Based on the submitted stability data WHO PQTm considers the following storage condition appropriate for the product when distributed in regions with zone III, IVa and IVb climatic conditions, based on available stability information:

- Do not store above 30°C. Store in the original package in order to protect from light and moisture.
- The shelf-life at this storage condition is 36 months.

This WHOPAR refers to the information available at the approving stringent regulatory authority's website resulting from the assessment of the quality, efficacy and safety as well as steps taken after approval. (<https://www.zva.gov.lv/en/healthcare-professionals-and-institutions/medicines/list-substances> PASS nātrija sāls Olpha 5,52 g )

For details on the uses of this product, for relevant efficacy and safety information see the summary of product characteristics and the patient information leaflet.

The English language version of the patient information leaflet, the summary of product characteristics and the labelling, as certified to be Latvian "Zāļu apraksts" approved texts, are included in this WHOPAR.

This WHOPAR for p-Aminosalicylate sodium 5.52 g powder is comprised of parts 2, 3, 4, 5 and 7.

p-Aminosalicylate sodium 5.52 g powder for oral solution contains p-aminosalicylate sodium dihydrate.

Its WHO recommended use is for treatment of tuberculosis in combination with other active agents.

**Summary of Prequalification Status for  
p-Aminosalicylate sodium 5.52 g powder for oral solution**

	Initial Acceptance		Requalification	
	Date	Outcome	Date	Outcome
Status on PQ list	22 March 2011	listed	08 May 2024	listed
Dossier Evaluation	March 2011	MR	May 2024	requalified
PQ: prequalification MR: meets requirements				

The table represents the status of relevant completed activities only.